Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genome-editing breakthroughs generate excitement—and lengthy disclosures. Sangamo Therapeutics’ risk factors span complex gene-editing platforms, trial data, and royalty-sharing with partners. If you’ve opened their 10-K and wondered, “Why is AAV vector safety buried on page 123?” you’re not alone. Stock Titan turns "Sangamo Therapeutics SEC filings explained simply" from wishful thinking into reality with AI-powered summaries that surface the questions investors actually ask.
Need the numbers fast? Our dashboard links every Sangamo Therapeutics quarterly earnings report 10-Q filing and delivers capsule revenue trends, cash-burn ratios, and pipeline spend in minutes. Drill into Form 4 details—"Sangamo Therapeutics insider trading Form 4 transactions"—and follow executives’ CRISPR-confidence in real time. AI tags each "Sangamo Therapeutics annual report 10-K simplified," highlights gene-editing milestones, and cross-references "Sangamo Therapeutics proxy statement executive compensation" so you can see how pay aligns with clinical progress. Even sudden study updates arrive instantly through "Sangamo Therapeutics 8-K material events explained."
Whether you’re modeling dilution risk or comparing partner economics, understanding Sangamo Therapeutics SEC documents with AI saves hours. Receive "Sangamo Therapeutics Form 4 insider transactions real-time" mobile alerts, launch side-by-side "Sangamo Therapeutics earnings report filing analysis," or track "Sangamo Therapeutics executive stock transactions Form 4" before the market reacts. With comprehensive coverage, expert commentary, and real-time EDGAR feeds, Stock Titan keeps genomic-medicine investors one step ahead—no molecular biology PhD required.
Sangamo Therapeutics (SGMO) reported positive topline data from its registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease. In 32 treated adults, a single infusion produced a mean annualized eGFR slope of +1.965 mL/min/1.73 m²/year at 52 weeks, contrasting with published slopes of -2.2 to -0.4 mL/min for current standard therapies. Among 19 patients with 104-week follow-up, the slope remained positive at +1.747 mL/min, the FDA-endorsed intermediate endpoint for Accelerated Approval.
Secondary outcomes were uniformly favorable. All 18 patients initially on enzyme-replacement therapy discontinued ERT and remained off treatment, while plasma lyso-Gb3, cardiac parameters and α-Gal A activity stayed stable or improved for up to 4.5 years. Patient-reported outcomes showed statistically significant gains across multiple SF-36 domains and reductions in gastrointestinal symptoms, pain-medication use and anhidrosis.
Safety profile appeared benign: most adverse events were grade 1-2; no pre-conditioning, no safety-related discontinuations. The most common TEAEs were pyrexia (60.6%), COVID-19 (36.4%), headache (33.3%) and nasopharyngitis (33.3%).
The dataset supports SGMO’s plan to file a BLA under the Accelerated Approval pathway as early as Q1 2026. ST-920 already holds Orphan Drug, Fast Track and RMAT designations, plus EU and UK incentives. Full analyses will be presented at a future conference, and management is pursuing a commercialization partnership.
FAQ
What is the current stock price of Sangamo Therapeutics (SGMO)?
What is the market cap of Sangamo Therapeutics (SGMO)?
What is the core focus of Sangamo Therapeutics Inc?
How does Sangamo generate clinical evidence?
What are the main therapeutic areas in Sangamo's pipeline?
How does Sangamo integrate research and clinical development?
What distinguishes Sangamo in the competitive biotech market?
What kind of diseases does Sangamo target with its therapies?
How is Sangamo’s innovation reflected in its business model?
